Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics.
Antifungal plant defensin technology platform.
Safe and effective application of the plant defensin technology to the treatment of human fungal disease.
Share price, ASX announcements and investor resources.